OncoBeta

OncoBeta® GmbH, founded in 2011, is a health and wellness and medical devices company that specializes in the development and commercialization of state-of-the-art therapies using epidermal radioisotopes. The company offers a pioneering solution known as the Rhenium-SCT® (Skin Cancer Therapy), which leverages the beta-emitter Rhenium-188 to provide a non-invasive and painless treatment option for non-melanoma skin cancers. This therapy, which has been CE certified and is backed by over 10 years of experience and clinical studies involving more than 700 patients and over 1900 lesions, has demonstrated a high level of effectiveness, with complete remissions achieved in up to 98.5% of cases. OncoBeta®'s innovative approach involves the local irradiation of tumors with Rhenium-188, which is known for its practical penetration of 2-3mm in human tissue, making it well-suited for treating superficial lesions such as non-melanoma skin cancers. The company's therapy is lauded for its minimal radiation exposure and adverse effects, offering patients a personalized brachytherapy experience that is both highly effective and aesthetically favorable. The company, based in Garching near Munich, is also exploring additional applications and treatment possibilities with Rhenium-188, further highlighting its commitment to leveraging its technology for the advancement of medical solutions in the field of epidermal radioisotope therapy. OncoBeta®'s continuous innovation and demonstrated success in non-surgical cancer treatment positions it as an impactful player in the medical devices industry, with significant potential for expansion and continued positive impact in the realm of cancer therapy.